Munoz-Espinosa L.E.,Autonomous University of Nuevo León |
Cordero-Perez P.,Autonomous University of Nuevo León |
Marin-Lopez E.,Hospital Beneficiencia Espanola |
Torres-Gonzalez L.,Autonomous University of Nuevo León |
And 6 more authors.
Archives of Medical Research | Year: 2013
Background and Aims: We undertook this study to evaluate the virological response to and presence of adverse events to natural interferon α (nIFNα; Multiferon®) treatment in previously nonresponsive Mexican patients chronically infected with genotype 1 hepatitis C. Methods: Thirty-nine patients received a 4-week induction of 5 days/week of 6 MU nIFNα plus weight-based ribavirin followed by 3 MU of nIFNα three times a week for 44 weeks. The relationship between viral response and incidence of adverse events was analyzed. Results: Early viral response (EVR) was age- and sex-dependent, with older male patients being less responsive. Sustained viral response (SVR) was evaluated according to: a) intention to treat analysis, b) 48-week treatment and 24-week follow-up (16 patients), and c) patients with EVR (11 patients). None of the factors was significantly different in groups a) and b); however, in group c) there was a better response with a marked viral load decline in younger patients and in patients aged 50 years and older. Five of 39 (13%) patients who completed treatment presented with an SVR. The most common adverse effect was asthenia in 27% of patients. Conclusions: nIFNα could be a useful strategy for re-treatment in chronic hepatitis C, genotype 1, in previously nonresponsive patients. Confirmation of these data in a larger population is required. © 2013 IMSS.
Flores-Valdez M.A.,Research Center istencia En Tecnologia seno Del Estado Of Jalisco Ac |
De Jesus Aceves-Sanchez M.,Research Center istencia En Tecnologia seno Del Estado Of Jalisco Ac |
Montero-Perez S.A.,Research Center istencia En Tecnologia seno Del Estado Of Jalisco Ac |
Sanchez-Lopez A.D.,National Autonomous University of Mexico |
And 2 more authors.
International Journal of Tuberculosis and Lung Disease | Year: 2012
Despite the availability of a Mycobacterium bovis bacille Calmette Guérin (BCG) vaccine, tuberculosis (TB) remains a global public health problem. In this study, we introduced the c-di-GMP phosphodiesterase gene Rv1357c, implicated in regulating mycobacterial replication within macrophages, into BCG Pasteur, and tested the resulting strain for its capacity to serve as a vaccine against TB in a murine model. Modified BCG was more phagocytosed than its parental strain, but halted bacterial replication, and protected against M. tuberculosis challenge similarly to unmodified BCG. © 2012 The Union.
Gutierrez-Mendoza D.,Hospital General Dr Manuel Gea Gonzalez |
De Anda Juarez M.,Hospital General Dr Manuel Gea Gonzalez |
Fonte Avalos V.,Hospital General Dr Manuel Gea Gonzalez |
Reyes Martinez G.,Hospital General Dr Manuel Gea Gonzalez |
Dominguez-Cherit J.,Instituto Nacional Of La Nutricion Y Ciencias Medicas Salvador Zubiran
Dermatologic Surgery | Year: 2015
BACKGROUND: Onychocryptosis is one of the most common painful nail conditions. Conservative treatment may take a long time to obtain effective results. OBJECTIVE: The purpose of this study is to show the effectiveness of a conservative treatment of ingrown nails that shows rapid results. METHODS AND MATERIALS: Patients with painful Stage 1 to 2 onychocryptosis who were not candidates or refused surgery were treated with the cotton cast. The severity and cause of onychocryptosis was clinically evaluated during a 2-month period. A questionnaire was applied to all patients to evaluate pain, final treatment, and possible complications. RESULTS: All patients noticed results in less than 72 hours. Pain subsided in less than 24 hours in half of the patients and before 72 hours in 100% of the patients without the need of other treatments. The use of the cast prevented surgery and the accompanying morbidities in most of the patients (80%). CONCLUSION: The "cotton nail cast" is an effective conservative method for mild nail embedding. It is easy to apply, inexpensive, relieves pain rapidly, and avoids surgery in most patients. © 2015 by the American Society for Dermatologic Surgery, Inc. Published by Wolters Kluwer Health, Inc. All rights reserved.